Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2000 Oct;41(10):1760-7.

Accuracy of 131I tumor quantification in radioimmunotherapy using SPECT imaging with an ultra-high-energy collimator: Monte Carlo study

Affiliations
Comparative Study

Accuracy of 131I tumor quantification in radioimmunotherapy using SPECT imaging with an ultra-high-energy collimator: Monte Carlo study

Y K Dewaraja et al. J Nucl Med. 2000 Oct.

Abstract

Accuracy of 131I tumor quantification after radioimmunotherapy (RIT) was investigated for SPECT imaging with an ultra-high-energy (UHE) collimator designed for imaging 511-keV photons.

Methods: First, measurements and Monte Carlo simulations were carried out to compare the UHE collimator with a conventionally used, high-energy collimator. On the basis of this comparison, the UHE collimator was selected for this investigation, which was carried out by simulation of spherical tumors in a phantom. Reconstruction was by an expectation-maximization algorithm that included scatter and attenuation correction. Keeping the tumor activity constant, simulations were carried out to assess how volume-of-interest (VOI) counts vary with background activity, radius of rotation (ROR), tumor location, and size. The constant calibration factor for quantification was determined from VOI counts corresponding to a 3.63-cm-radius sphere of known activity. Tight VOIs corresponding to the physical size of the spheres or tumors were used.

Results: Use of the UHE collimator resulted in a large reduction in 131I penetration, which is especially significant in RIT where background uptake is high. With the UHE collimator, typical patient images showed an improvement in contrast. Considering the desired geometric events, sensitivity was reduced, but only by a factor of 1.6. Simulation results for a 3.63-cm-radius tumor showed that VOI counts vary with background, location, and ROR by less than 3.2%, 3%, and 5.3%, respectively. The variation with tumor size was more significant and was a function of the background. Good quantification accuracy (<6.5% error) was achieved when tumor size was the same as the sphere size used in the calibration, irrespective of the other parameters. For smaller tumors, activities were underestimated by up to -15% for the 2.88-cm-radius sphere, -23% for the 2.29-cm-radius sphere, and -47% for the 1.68-cm-radius sphere.

Conclusion: Reasonable accuracy can be achieved for VOI quantification of 131I using SPECT with an UHE collimator and a constant calibration factor. Difference in tumor size relative to the size of the calibration sphere had the biggest effect on accuracy, and recovery coefficients are needed to improve quantification of small tumors.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
(A) Simulated phantom consists of hot sphere centered in elliptic phantom. (B) Center plane of phantom shows 3 sphere locations.
FIGURE 2
FIGURE 2
131I point source energy spectrum for 2 collimators.
FIGURE 3
FIGURE 3
131I point source planar image measured with HE collimator (A) and UHE collimator (B). (C) Profiles from (A) and (B) and simulated profile for UHE collimator.
FIGURE 4
FIGURE 4
Reconstructed slice in abdominal region of patient imaged with HE collimator (A) and UHE collimator (B) after 131I RIT. Rt K = right kidney; Lf K = left kidney. (C) Profiles from (A) and (B).
FIGURE 5
FIGURE 5
Tumor VOI counts as function of b with and without scatter correction for 3.63-cm-radius sphere.

Similar articles

Cited by

References

    1. Wahl RL, Zasadny KR, McFarlane D, et al. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan phase I experience. J Nucl Med. 1998;39(suppl 8):21S–27S. - PubMed
    1. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti B1 radioimmuno-therapy for B-cell lymphoma. J Clin Oncol. 1996;14:1974–1981. - PubMed
    1. DeNardo GL, Lamborn KR, Goldstein DS, Kroger LA, DeNardo SJ. Increased survival associated with radiolabeled lym-1 therapy for non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Cancer. 1997;80:2706–2711. - PubMed
    1. Press O, Early J, Appelbaum F, et al. Phase II trial of I-131 B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphomas. Lancet. 1995;346:336–340. - PubMed
    1. Koral KF, Zasadny KR, Kessler ML, et al. CT-SPECT fusion plus conjugate views for determining dosimetry in iodine-131-monoclonal antibody therapy of lymphoma patients. J Nucl Med. 1994;35:1714–1720. - PubMed

Publication types

Substances

LinkOut - more resources